載入...
Risk of de novo hepatocellular carcinoma following use of direct acting antiviral medications for treatment of chronic hepatitis C
Direct-acting antivirals (DAA) are now the mainstay of treatment for patients with chronic hepatitis C virus (HCV); however, there is some controversy over whether use of DAAs for HCV, as compared with interferon (IFN)-based regimens, leads to an increased risk of hepatocellular carcinoma (HCC) deve...
Na minha lista:
| 發表在: | Cancer Prev Res (Phila) |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6893130/ https://ncbi.nlm.nih.gov/pubmed/31451519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-19-0162 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|